Drapkin Kimberlee C 4
4 · Acumen Pharmaceuticals, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Acumen (ABOS) Director Kimberlee Drapkin Receives Stock Awards
What Happened
Kimberlee C. Drapkin, a director of Acumen Pharmaceuticals, was granted two award-type awards on 2026-06-03: 35,500 restricted stock units (RSUs) and 53,250 derivative awards (reported as an acquisition at $0.00). Both awards were reported on a Form 4 filed 2026-06-05. The reported acquisition price for both items is $0.00 (i.e., these are grants/awards rather than open-market purchases).
Key Details
- Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
- Grants: 35,500 RSUs (acquired at $0.00) and 53,250 derivative awards (acquired at $0.00).
- Shares/ownership after transaction: not specified in the provided filing excerpt.
- Footnotes:
- F1: The 35,500 are RSUs; each RSU converts to one common share upon vesting. Vesting occurs on the earlier of the first anniversary of grant or the 2027 annual stockholder meeting, subject to continuous service.
- F2: The 53,250 are derivative (shares subject to an option); vesting follows the same schedule/conditions as F1.
- No indication of a sale, cash exercise, tax withholding, 10b5-1 plan, or other disposition in the excerpt.
Context
These awards are equity compensation grants, not open-market purchases or sales. RSUs represent a contingent right to receive shares if vesting conditions are met; the derivative award appears to be an option-like grant that also vests on a similar schedule. Such grants are common for directors and reflect compensation arrangements rather than immediate personal investment or liquidation.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-03+35,500→ 48,300 total - Award
Stock Option (right to buy)
[F2]2026-06-03+53,250→ 53,250 totalExercise: $2.29Exp: 2036-06-03→ Common Stock (53,250 underlying)
Footnotes (2)
- [F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
- [F2]The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.